The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2019

Filed:

Nov. 09, 2012
Applicant:

Fred Hutchinson Cancer Research Center, Seattle, WA (US);

Inventors:

Philip Greenberg, Mercer Island, WA (US);

Sebastian Ochsenreither, Berlin, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 9/127 (2006.01); C07K 7/08 (2006.01); A61K 39/00 (2006.01); C12N 9/12 (2006.01); C07K 14/47 (2006.01); C07K 7/06 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 14/4738 (2013.01); C12N 9/12 (2013.01); A61K 38/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5158 (2013.01);
Abstract

Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.


Find Patent Forward Citations

Loading…